ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
VIENNA, Austria, Jan. 05, 2018 -- APEIRON Biologics AG, a company focused on cancer immunotherapy, today announced that it will present at Biotech Showcase™ 2018, to be held January 8–10 at the Hilton San Francisco Union Square during one of the most important weeks in healthcare investing.
APEIRON Biologics AG will present at the Biotech Showcase™ as follows:
Date: Tuesday, January 9, 2018
Time: 1:45 p.m. (PST)
Room: Franciscan D, Ballroom Level
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
In San Francisco, management will conduct a large number of meetings with healthcare investors. If you would like to schedule a meeting, please feel free to reach out to one of the contacts listed at the end of this press release.
About APEIRON Biologics AG
Apeiron is a private biotech company based in Vienna, Austria, engaged in innovative projects in immuno-oncology. Recently, the most advanced program, an antibody-based immunotherapy to treat neuroblastoma, was granted marketing approval in the EU. The company is developing additional immunotherapies, predominantly in clinical stage, based either on targeted, tumor-specific approaches or on the stimulation of the immune system via novel and proprietary modes of action (unique checkpoint blockade mechanisms) to fight cancer by engaging the human body’s natural defense mechanisms. For additional information please go to www.apeiron-biologics.com and follow us on Twitter @apeironbio.
For further information please contact:
APEIRON Biologics AG
Peter Llewellyn-Davies, CFO/CBO
Email: [email protected]
www.apeiron-biologics.com
Investor Relations
LifeSci Advisors, LLC
Chris Maggos
T +1 (646) 597 6989
Email: [email protected]
Media Relations international
MC Services AG
Dr. Claudia Gutjahr-Loeser
T +49 89 210 228 0
Email: [email protected]
Media Relations Austria:
PR&D - Public Relations for Research & Education
T +43 1 505 70 44
Email: [email protected]
